Statute
Patent Act
152 published works
Healthcare Law Insights
AI Innovations and Patent Eligibility in the Life Sciences: Understanding the Underlying Legal Framework
Artificial intelligence (AI) is transforming industries, including the life sciences industry, from drug discovery and diagnostics to medical devices and manufacturing. With that transformation comes a critical challenge: crafting strategies…
Spicy IP
SpicyIP Tidbit: All Eyes on Kerala HC’s Final Hearing in the Ribociclib Matter Today
By SpicyIP
image from here [This post is authored by Rishabh Upadhyay. Rishabh is an LL.M. candidate at the Faculty of Law, Delhi University, having completed his undergraduate legal studies at the…
Patent Law Weblog
Exelixis, Inc. v. MSN Laboratories Private Ltd. (Fed. Cir. 2026)
By Kevin E. Noonan –Written description jurisprudence has been one of the areas of statutory explication of Section 112(a) (along with enablement) primarily under the purview of the Federal Circuit…
Founders Legal Blog
Claude’s AI Watermark and the Patent Risks Founders Should Understand
Claude’s AI Watermark and the Patent Risks Founders Should Understand by Yuri L. Eliezer Claude’s AI Watermark and the Patent Risks Founders Should Understand Claude’s AI watermark is not a…
Founders Legal Blog
Patent Protection Before Filing
Patent Protection Before Filing by Kevin Bastuba Patent Protection Before Filing: Inventorship, Ownership, and AI-Assisted Innovation AI-assisted innovation has changed the way inventions are developed. A solo inventor can test…
Patent Law Weblog
Improving the Abstract Idea: How a Rhetorical Move Undermines § 101 Analysis of Technical Improvements in Software Inventions
By Michael Borella – More than a decade after Alice Corp. v. CLS Bank Int’l, the two-step framework for patent eligibility under 35 U.S.C. § 101 remains as contentious as…
Patent Law Weblog
Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc. (Fed. Cir. 2026)
By Kevin E. Noonan – The Federal Circuit affirmed a District Court determination that method claims reciting administration of a modification of an established antibiotic by adding magnesium to the…
Big Molecule Watch
Amneal and Kashiv File IPR Petition on Omalizumab Patent
By Timothy Beavers|Josh Eibelman
On May 26, 2026, Amneal Pharmaceuticals, Inc. and Kashiv Biosciences petitioned for inter partes review (IPR2026-00260) of all claims of U.S. Patent No. 12,030,959 (“the ’959 patent”), assigned to Novartis…
PTABWatch
The Futility in Appealing PTAB Institution Decisions
Last month, in Federal Express Corp. v. Qualcomm Inc., Appeal No. 2024‑1236 (Fed. Cir. Apr. 29, 2026), the Federal Circuit again addressed the reach of the statutory bar on its…
Spicy IP
SpicyIP Weekly Review (May 4 – May 10)
Into the second week of May with a post on the Bombay HC’s reliance on section 65 for setting aside a refusal of atomic energy patent. Another post examining the…